TY - JOUR
T1 - Performance of AGO score for secondary cytoreduction in a high-volume U.S. center
AU - Janco, Jo Marie Tran
AU - Kumar, Amanika
AU - Weaver, Amy L.
AU - McGree, Michaela E.
AU - Cliby, William A.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Objectives Determine the predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score, and prognostic factors for survival, in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer in a high-volume U.S. center. Methods Medical records of women undergoing SCS between 12/1/1998 and 12/31/2013 were reviewed. Women with no gross residual disease (RD0) at primary surgery, ECOG performance status (PS) ≤ 1 at recurrence, and no ascites on CT at recurrence were classified as AGO score positive. Women with incomplete information to determine the AGO score were excluded. Overall survival (OS) and progression-free survival (PFS) following SCS, respectively, were estimated from multivariable Cox proportional hazards models. Results 192 women met inclusion criteria. Median disease-free interval (DFI) was 1.9 years (IQR, 1.0-3.5). Of the 102 (53.1%) AGO score positive cases, 84.3% (95% CI, 77.3-91.4%) achieved RD0 at SCS. However, 64.4% of AGO score negative cases also reached RD0. Patients with RD0 after SCS survived longer (median OS, 5.4 years) vs. RD ≤ 1 cm (2.4 years) vs. RD > 1 cm (1.3 years) (p < 0.001). Median PFS was also longer in patients with RD0 (1.5 years) vs. RD ≤ 1 cm (0.9 years) vs. RD > 1 cm (1.0 years) (p = 0.001). Among those with RD0 at SCS, AGO score was not associated with survival benefit, however, number of disease sites at recurrence, ECOG PS at recurrence, and DFI were associated with OS and PFS. Conclusions AGO score can identify patients with a high likelihood of complete secondary cytoreduction and improved survival. However, most AGO score negative cases were also completed resected at SCS. Additional refinement of the score is needed to exclude women from SCS.
AB - Objectives Determine the predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score, and prognostic factors for survival, in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer in a high-volume U.S. center. Methods Medical records of women undergoing SCS between 12/1/1998 and 12/31/2013 were reviewed. Women with no gross residual disease (RD0) at primary surgery, ECOG performance status (PS) ≤ 1 at recurrence, and no ascites on CT at recurrence were classified as AGO score positive. Women with incomplete information to determine the AGO score were excluded. Overall survival (OS) and progression-free survival (PFS) following SCS, respectively, were estimated from multivariable Cox proportional hazards models. Results 192 women met inclusion criteria. Median disease-free interval (DFI) was 1.9 years (IQR, 1.0-3.5). Of the 102 (53.1%) AGO score positive cases, 84.3% (95% CI, 77.3-91.4%) achieved RD0 at SCS. However, 64.4% of AGO score negative cases also reached RD0. Patients with RD0 after SCS survived longer (median OS, 5.4 years) vs. RD ≤ 1 cm (2.4 years) vs. RD > 1 cm (1.3 years) (p < 0.001). Median PFS was also longer in patients with RD0 (1.5 years) vs. RD ≤ 1 cm (0.9 years) vs. RD > 1 cm (1.0 years) (p = 0.001). Among those with RD0 at SCS, AGO score was not associated with survival benefit, however, number of disease sites at recurrence, ECOG PS at recurrence, and DFI were associated with OS and PFS. Conclusions AGO score can identify patients with a high likelihood of complete secondary cytoreduction and improved survival. However, most AGO score negative cases were also completed resected at SCS. Additional refinement of the score is needed to exclude women from SCS.
KW - Recurrent ovarian cancer
KW - Secondary cytoreduction
UR - http://www.scopus.com/inward/record.url?scp=84957084308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957084308&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2016.01.027
DO - 10.1016/j.ygyno.2016.01.027
M3 - Article
C2 - 26836496
AN - SCOPUS:84957084308
SN - 0090-8258
VL - 141
SP - 140
EP - 147
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -